dc.contributor.author | Guney, N. | |
dc.contributor.author | Sakar, B. | |
dc.contributor.author | Gumus, M. | |
dc.contributor.author | Argon, A. | |
dc.contributor.author | Ustuner, Z. | |
dc.contributor.author | Ustaoglu, M. A. | |
dc.contributor.author | Saglam, S. | |
dc.contributor.author | Tenekeci, A. N. | |
dc.contributor.author | Aykan, N. F. | |
dc.contributor.author | Basaran, M. | |
dc.date.accessioned | 2021-03-04T09:32:57Z | |
dc.date.available | 2021-03-04T09:32:57Z | |
dc.identifier.citation | Sakar B., Gumus M., Basaran M., Argon A., Ustuner Z., Ustaoglu M. A. , Saglam S., Guney N., Tenekeci A. N. , Aykan N. F. , "XELOX followed by XELIRI or the reverse sequence in advanced colorectal cancer", ONCOLOGY, cilt.73, ss.298-304, 2007 | |
dc.identifier.issn | 0030-2414 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_68c05bd4-550d-4878-a37a-0e909d139b3f | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/72595 | |
dc.identifier.uri | https://doi.org/10.1159/000132395 | |
dc.description.abstract | Background: Capecitabine has demonstrated high efficacy as first-line treatment for metastatic colorectal cancer (mCRC). In this non-randomized pilot study, we investigated the efficacy and safety of sequentially administered XELOX and XELIRI regimens or the reverse sequence in patients with advanced colorectal cancer. Patients and Methods: Entry criteria were histologically confirmed mCRC, ECOG performance status (PS) <= 2 and adequate bone marrow, renal and hepatic function. All patients consecutively received XELOX followed by XELIRI at disease progression or vice versa. Results: In multivariate analysis, independent prognostic factors with worse overall survival were: lower PS (p = 0.0001), multiple metastatic sites (p = 0.016) and high tumor grade. Higher serum levels of alkaline phosphatase and worse ECOG PS were associated with a shorter progression-free survival. Grade 3/4 mucositis, nausea/vomiting, grade 3/4 alopecia and grade 3 diarrhea were more frequent with XELIRI, whereas major toxicity events with XELOX were grade 3 neutropenia, thrombocytopenia and grade 2/3 neurotoxicity. Conclusion: Capecitabine appears to be an acceptable alternative to continuous-infusion fluorouracil (FU)/leucovorin (LV) in combination therapy and offers an effective, but more convenient alternative to continuous infusion FU/LV in the first-line treatment of patients with mCRC. Copyright (c) 2008 S. Karger AG, Basel. | |
dc.language.iso | eng | |
dc.subject | Sağlık Bilimleri | |
dc.subject | İç Hastalıkları | |
dc.subject | Onkoloji | |
dc.subject | ONKOLOJİ | |
dc.subject | Klinik Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Tıp | |
dc.subject | Dahili Tıp Bilimleri | |
dc.title | XELOX followed by XELIRI or the reverse sequence in advanced colorectal cancer | |
dc.type | Makale | |
dc.relation.journal | ONCOLOGY | |
dc.contributor.department | Istanbul Kartal Dr Lutfi Kirdar Training & Research Hospital , , | |
dc.identifier.volume | 73 | |
dc.identifier.startpage | 298 | |
dc.identifier.endpage | 304 | |
dc.contributor.firstauthorID | 181498 | |